Literature DB >> 14669323

Heterologous expression of human cytochrome P450 2E1 in HepG2 cell line.

Jian Zhuge1, Ye Luo, Ying-Nian Yu.   

Abstract

AIM: Human cytochrome P-450 2E1 (CYP2E1) takes part in the biotransformation of ethanol, acetone, many small-molecule substrates and volatile anesthetics. CYP2E1 is involved in chemical activation of many carcinogens, procarcinogens, and toxicants. To assess the metabolic and toxicological characteristics of CYP2E1, we cloned CYP2E1 cDNA and established a HepG2 cell line stably expressing recombinant CYP 2E1.
METHODS: Human CYP2E1 cDNA was amplified with reverse transcription-polymerase chain reaction (RT-PCR) from total RNAs extracted from human liver and cloned into pGEM-T vector. The cDNA segment was identified by DNA sequencing and subcloned into a mammalian expression vector pREP9. A transgenic cell line was established by transfecting the recombinant plasmid of pREP9-CYP2E1 to HepG2 cells. The expression of CYP2E1 mRNA was validated by RT-PCR. The enzyme activity of CYP2E1 catalyzing oxidation of 4-nitrophenol in postmitochondrial supernate (S9) fraction of the cells was determined by spectrophotometry. The metabolic activation of HepG2-CYP2E1 cells was assayed by N-nitrosodiethylamine (NDEA) cytotoxicity and micronucleus test.
RESULTS: The cloned CYP2E1 cDNA segment was identical to that reported by Umeno et al (GenBank access No. J02843). HepG2-CYP2E1 cells expressed CYP2E1 mRNA and had 4-nitrophenol hydroxylase activity (0.162 +/- 0.025 nmol.min(-1).mg(-1) S9 protein), which were undetectable in parent HepG2 cells. HepG2-CYP2E1 cells increased the cytotoxicity and micronucleus rate of NDEA in comparison with those of HepG2 cells.
CONCLUSION: The cDNA of human CYP2E1 can be successfully cloned, and a cell line, HepG2-CYP2E1, which can efficiently express mRNA and has CYP2E1 activity, is established. The cell line is useful for testing the cytotoxicity, mutagenicity and metabolism of xenobiotics, which may possibly be activated or metabolized by CYP2E1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669323      PMCID: PMC4612042          DOI: 10.3748/wjg.v9.i12.2732

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  A protocol for the in vitro micronucleus test. I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity.

Authors:  Michael L Garriott; J Barry Phelps; Wherly P Hoffman
Journal:  Mutat Res       Date:  2002-05-27       Impact factor: 2.433

Review 2.  Development and validation of alternative metabolic systems for mutagenicity testing in short-term assays.

Authors:  J Rueff; C Chiapella; J K Chipman; F Darroudi; I D Silva; M Duverger-van Bogaert; E Fonti; H R Glatt; P Isern; A Laires; A Léonard; M Llagostera; P Mossesso; A T Natarajan; F Palitti; A S Rodrigues; A Schinoppi; G Turchi; G Werle-Schneider
Journal:  Mutat Res       Date:  1996-06-12       Impact factor: 2.433

3.  Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing.

Authors:  Jian Zhu-Ge; Ying-Nian Yu; Yu-Li Qian; Xin Li
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

4.  Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk.

Authors:  Loïc Le Marchand; Timothy Donlon; Ann Seifried; Lynne R Wilkens
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-10       Impact factor: 4.254

5.  Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells.

Authors:  Ge-Jian Zhu; Ying-Nian Yu; Xin Li; Yu-Li Qian
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

6.  Cloning of UGT1A9 cDNA from liver tissues and its expression in CHL cells.

Authors:  X Li; Y N Yu; G J Zhu; Y L Qian
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

7.  Cytochrome P450 2E1 genetic polymorphism and gastric cancer in Changle, Fujian Province.

Authors:  L Cai; S Z Yu; Z F Zhan
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

8.  Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a.

Authors:  D R Koop
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

9.  HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures.

Authors:  M Fenech; W P Chang; M Kirsch-Volders; N Holland; S Bonassi; E Zeiger
Journal:  Mutat Res       Date:  2003-01-10       Impact factor: 2.433

10.  Detection and characterization of novel polymorphisms in the CYP2E1 gene.

Authors:  K S Fairbrother; J Grove; I de Waziers; D T Steimel; C P Day; C L Crespi; A K Daly
Journal:  Pharmacogenetics       Date:  1998-12
View more
  4 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  Three new alternative splicing variants of human cytochrome P450 2D6 mRNA in human extratumoral liver tissue.

Authors:  Jian Zhuge; Ying-Nian Yu
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

3.  Thirdhand smoke causes DNA damage in human cells.

Authors:  Bo Hang; Altaf H Sarker; Christopher Havel; Saikat Saha; Tapas K Hazra; Suzaynn Schick; Peyton Jacob; Virender K Rehan; Ahmed Chenna; Divya Sharan; Mohamad Sleiman; Hugo Destaillats; Lara A Gundel
Journal:  Mutagenesis       Date:  2013-03-05       Impact factor: 3.000

Review 4.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.